BCPEM
MRTX

Bain Capital Public Equity Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bain Capital Public Equity Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-55,564
Closed -$2.36M – 78
2018
Q4 		$2.36M Sell
55,564
-237,224
-81% -$9.45M 0.22% 42
2018
Q3 		$13.8M Buy
+292,788
New +$16.3M 0.97% 25

Other funds holding MRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bain Capital Public Equity Management's MRTX Position: Q1 2019 in Review

Bain Capital Public Equity Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2019, closing a stake of 55,564 shares — an estimated $2.36M sold.

Bain Capital Public Equity Management first reported a position in MRTX in Q3 2018 and held it in 2 quarters. The position peaked at $13.8M in Q3 2018. 159 funds tracked by Wall St. Rank hold MRTX as of Q1 2019.

  • Bain Capital Public Equity Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Bain Capital Public Equity Management sold 55,564 Mirati Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $2.36M.
  • Bain Capital Public Equity Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • Bain Capital Public Equity Management's Mirati Therapeutics, Inc. Common Stock position peaked at $13.8M in Q3 2018.
  • 159 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Bain Capital Public Equity Management's 13F filing for Q1 2019, filed 15 May 2019.